Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Doxorubicin, Paclitaxel, and Carboplatin in Treating Patients With Primary Stage III, Stage IV, or Recurrent Endometrial Cancer

This study has been completed.
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by:
Memorial Sloan Kettering Cancer Center
ClinicalTrials.gov Identifier:
NCT00006377
First received: October 4, 2000
Last updated: June 17, 2013
Last verified: June 2013
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: January 2003
  Primary Completion Date: January 2003 (Final data collection date for primary outcome measure)